目的 探讨卵巢癌患者、卵巢良性疾病及健康成人女性调节性T细胞（Tregs）和肿瘤标志物CA125、CA19-9水平的差异，并将其与临床病理因素及预后进行相关分析。 方法 选择2016年10月~2017年10月承德医学院附属医院妇科收治的经病理确诊的卵巢癌患者43例，设为恶性组，另选择同期医院收治的卵巢良性疾病患者55例作为良性组，健康体检妇女50例作为对照组。比较3组患者Tregs和肿瘤标志物CA125、CA199在卵巢癌患者中的表达水平，分析其与临床病理因素及预后的关系。 结果 恶性组和良性组Tregs比例、CA125和CA19-9水平均高于对照组，恶性组Tregs比例、CA125和CA19-9水平高于良性组（P<0.05）。CA125、CA19-9、Tregs水平与患者的年龄差异无显著性（P>0.05）；CA125水平与卵巢癌患者的淋巴结是否转移、肿瘤分期和组织学类型均有关；Tregs表达水平与卵巢癌患者的淋巴结是否转移和肿瘤分期均相关，CA19-9水平只与肿瘤分期相关（P<0.05）。随访12个月后，Tregs-low组中位生存时间高于Tregs-high组（P<0.05）。卵巢癌中Tregs数与CA125存在显著正相关性（P<0.05），而与CA19-9不具有相关性（P>0.05）。结论 Tregs、CA125和CA19-9均可有望成为卵巢癌临床诊断、治疗和预后的指标。

Objective To investigate the difference of ovarian benign diseases and healthy regulatory T cells(Tregs) and tumor markers CA125 and CA19-9 in patients with ovarian cancer, and to analyze their correlation with clinicopathological factors and prognosis. Methods We selected 43 cases pathologically diagnosed ovarian cancer patients in gynecological department from October 2016 to October 2017 in our hospital as a malignant group, another 55 cases of benign ovarian patients treated in the same period as benign group, 50 cases of healthy physical examination women as control group. The Tregs number and expression levels of tumor markers CA125 and CA19-9 in ovarian cancer were compared among the three groups, and their relationship with clinicopathological factors and prognosis was analyzed. Results The proportions of Tregs in the malignant and benign groups were higher than those in the control group, and the proportions of Tregs, CA125 and CA19-9 in the malignant group were higher than that in the benign group (P<0.05). There are no significant difference in the proportion of Tregs, CA125 and CA19-9 levels and the age of patients. The level of CA125 was related to the lymph node metastasis, tumor stage, and histological type in patients with ovarian cancer. Tregs ratio was associated with lymph node metastasis and tumor staging in patients with ovarian cancer. The CA19-9 level was only related to tumor stage (P<0.05). After 12 months of follow-up, the median survival time of Tregs low group was higher than that of Tregs high group (P<0.05).There was a significant positive correlation between the number of Tregs and CA125 in ovarian cancer (P<0.05), but not with CA19-9 (P>0.05). Conclusion Tregs, CA125, and CA19-9 can all be promising markers for clinical diagnosis, treatment and prognosis of ovarian cancer.